DOP80 Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor: A multi-centre comparative study
ECCO'20 Vienna
2020
DOP82 Macrophages in Crohn’s disease mesentery are predominantly inflammatory and produce calprotectin
ECCO'20 Vienna
2020
DOP83 Intestinal fibrosis in Crohn’s disease patients is marked by up-regulation of innate immune cells and mucosal B cells
ECCO'20 Vienna
2020
DOP84 Crohn’s disease modifies the DNA methylome of human adipose-stem cells, which is only partially re-established in remission
ECCO'20 Vienna
2020
DOP85 The role of fibroblasts in the pathogenesis of Crohn’s disease-associated fistulas and in mesenchymal stem cell therapy
ECCO'20 Vienna
2020
DOP86 An IFN-STAT1-MLKL axis drives programmed necrosis of Paneth cells in Crohn’s ileitis
ECCO'20 Vienna
2020
DOP88 Visceral fat area correlates well with anti-TNFα drug levels and secondary loss of response in Crohn’s disease patients
ECCO'20 Vienna
2020
N01 Factors related to self-medication with corticosteroids, aminosalicylates or analgesics and reasons given by patients with ulcerative colitis from Spain
ECCO'20 Vienna
2020
N02 The IBD-BOOST programme: developing a digital self-management intervention for symptoms of fatigue, pain and urgency in inflammatory bowel disease
ECCO'20 Vienna
2020
N03 Disease burden of patients with inflammatory bowel disease from the viewpoint of QOL and depression
ECCO'20 Vienna
2020